Skip to main content

Alpine Immune Sciences, Inc. (ALPN)

NASDAQ: ALPN · IEX Real-Time Price · USD
10.61 -0.05 (-0.47%)
Sep 24, 2021 10:38 AM EDT - Market open
Market Cap242.98M
Revenue (ttm)17.95M
Net Income (ttm)-34.15M
Shares Out23.91M
EPS (ttm)-1.46
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume46,950
Open10.97
Previous Close10.66
Day's Range10.58 - 10.98
52-Week Range7.21 - 16.37
Beta1.73
AnalystsStrong Buy
Price Target20.00 (+88.5%)
Est. Earnings DateNov 11, 2021

About ALPN

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B...

IndustryBiotechnology
CEOCharles Scoggin
Employees57
Stock ExchangeNASDAQ
Ticker SymbolALPN
Full Company Profile

Financial Performance

In 2020, ALPN's revenue was $9.34 million, an increase of 436.49% compared to the previous year's $1.74 million. Losses were -$27.94 million, -33.24% less than in 2019.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for ALPN stock is "Strong Buy." The 12-month stock price forecast is 20.00, which is an increase of 88.50% from the latest price.

Price Target
$20.00
(88.50% upside)
Analyst Consensus: Strong Buy

News

Alpine Immune Sciences Announces $91 Million Private Placement

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory di...

1 week ago - Business Wire

Alpine Immune Sciences Announces Participation in September Investor Conferences

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Announces Participation in September Investor Conferences

2 weeks ago - Business Wire

Alpine Immune Sciences, Inc. (ALPN) Reports Q2 Loss, Tops Revenue Estimates

Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -58.62% and 9.15%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Alpine Immune Sciences: Q2 Earnings Insights

Shares of Alpine Immune Sciences (NASDAQ:ALPN) moved higher in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 13.21% year over year to ($0.46), whi...

1 month ago - Benzinga

Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2021 Financial Results

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2021 Financial Results

1 month ago - Business Wire

Alpine Immune Sciences to Report Second Quarter 2021 Financial Results and to Present at Upcoming Investor Conferences

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Report Second Quarter 2021 Financial Results and to Present at Upcoming Investor Conferences

1 month ago - Business Wire

Will Alpine Immune Sciences, Inc. (ALPN) Report Negative Q2 Earnings? What You Should Know

Alpine Immune Sciences, Inc. (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Alpine Immune Sciences Initiates Trial Collaboration With Merck

Alpine Immune Sciences Inc (NASDAQ: ALPN) has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK).  This collaboration will evaluate the safety and efficacy ...

Other symbols:MRK
2 months ago - Benzinga

Alpine Immune Sciences to Collaborate with Merck on Immuno-Oncology Study to Evaluate ALPN-202 in Combination with KE...

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Collaborate with Merck on Immuno-Oncology Study to Evaluate ALPN-202 in Combination with KEYTRUDA® (pembrolizumab)

2 months ago - Business Wire

Alpine Immune Sciences Announces First Patient Dosed in Synergy, ALPN-101 Phase 2 Lupus Clinical Trial and $45 millio...

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Announces First Patient Dosed in Synergy, ALPN-101 Phase 2 Lupus Clinical Trial and $45 million in Development Milestones

3 months ago - Business Wire

Forget Biogen: These 2 Under-the-Radar Biotechs Are Also Celebrating Breakthroughs

Biogen isn't the only company whose shares should benefit from a breakthrough drug.

Other symbols:ALKS
3 months ago - The Motley Fool

Alpine Immune Sciences Set to Join Russell 3000® Index

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences set to join Russell 3000® Index

3 months ago - Business Wire

Alpine Immune Sciences Announces ALPN-202 Clinical Data Presented at the 2021 ASCO Virtual Annual Meeting

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Announces ALPN-202 Clinical Data Presented at the 2021 ASCO Virtual Annual Meeting

3 months ago - Business Wire

Alpine Immune Sciences' Autoimmune Disease Candidate ALPN-303 Shows Promise in Preclinical Studies

Alpine Immune Sciences Inc (NASDAQ: ALPN) has presented the preclinical data from its ALPN-303 program at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology...

3 months ago - Benzinga

Alpine Immune Sciences Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Presents ALPN-303 Data During the 2021 EULAR Virtual Meeting

3 months ago - Business Wire

Alpine Immune Sciences Appoints Zelanna Goldberg, M.D., M.A.S. as Chief Medical Officer

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Appoints Zelanna Goldberg, M.D., M.A.S. as Chief Medical Officer

3 months ago - Business Wire

3 Biotech Stocks That Jumped Higher Last Week

Find out what pushed them up to see if the good times can keep rolling.

Other symbols:AGENANVS
4 months ago - The Motley Fool

Alpine Immune Sciences, Inc. (ALPN) Moves 9.5% Higher: Will This Strength Last?

Alpine Immune Sciences, Inc. (ALPN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could ...

4 months ago - Zacks Investment Research

Alpine Immune Sciences To Host Investor Event at 2021 ASCO Virtual Annual Meeting

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences To Host Investor Event at 2021 ASCO Virtual Annual Meeting

4 months ago - Business Wire

Alpine Immune Sciences Announces Oral Presentation at the 2021 EULAR Virtual Meeting

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Announces Oral Presentation at the 2021 EULAR Virtual Meeting

4 months ago - Business Wire

Alpine Immune Sciences, Inc. (ALPN) Reports Q1 Loss, Lags Revenue Estimates

Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -40.63% and -45.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the ...

4 months ago - Zacks Investment Research

Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2021 Financial Results

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2021 Financial Results

4 months ago - Business Wire

Earnings Preview: Alpine Immune Sciences, Inc. (ALPN) Q1 Earnings Expected to Decline

Alpine Immune Sciences, Inc. (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

Alpine Immune Sciences to Present ALPN-202 Clinical Data at the 2021 ASCO Virtual Annual Meeting

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences to Present ALPN-202 Clinical Data at the 2021 ASCO Virtual Annual Meeting

4 months ago - Business Wire

Is the Options Market Predicting a Spike in Alpine (ALPN) Stock?

Investors need to pay close attention to Alpine (ALPN) stock based on the movements in the options market lately.

5 months ago - Zacks Investment Research